Fast Locator 2014-2015: Jubilant - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Fast Locator 2014-2015: Jubilant


Jubilant HollisterStier

Description:
Jubilant HollisterStier Pharma Solutions is a global manufacturing service provider, able to aseptically fill liquid, lyophilized, semi-solid and solid dosage forms in our facilities across North America and India.  Jubilant HollisterStier Pharma Solutions represents the CMOs formally branded as HollisterStier Contract Manufacturing and Draxis Pharma, as well as non-branded solid dosage sites in Maryland and India. New branded name and logo,
same quality service. 

Quality is part of Jubilant HollisterStier's corporate culture and is held to a high standard throughout our facilities.  We provide a full-range of support and services to streamline the manufacturing process such as on-site assistance from process qualifications and regulatory submittals through product release. Jubilant HollisterStier’s Quality Unit maintains an integrated quality assurance program that emphasizes quality design, validation and proper use of facilities and equipment.

Certified Project Managers work with our clients and our expert staff throughout the manufacturing process to ensure that projects are processed efficiently and safely.  We are committed to providing exceptional quality, regulatory expertise and operational excellence to ensure streamlined processes and services in all facilities.

For more information about Jubilant HollisterStier Pharma Solutions, please visit HScontract.com.

Website:
www.HScontract.com

Services Provided:

Sterile Fill/FinishSpokane, WA
Phase I-commercial sterile injectables, lyophilization

Sterile and non-sterile Fill/FinishMontreal, Quebec, Canada
Commercial sterile injectables, lyophilization and opthalmics
Non-sterile topical creams/ointments and liquids

Small Volume- Commercial Solid DosageSalisbury, Maryland, USA
Tablets, capsules

Large Volume Solid DosageRoorkee, India
Tablets and capsules

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here